Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type NSCLC and Enriched ORRs in Patients with High c-Met Expression
Findings from the LUMINOSITY study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with Primary Advanced or Recurrent Endometrial Cancer
It is intended for the first-line treatment of patients who are candidates for systemic therapy, followed by maintenance treatment
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in Patients with Previously Treated Advanced or Metastatic NSCLC
Findings from the EVOKE-01 study
AI-Based Score as a Selection Tool for Supplemental MRI After Negative Mammography Detects Many Missed Breast Cancers
Findings from the ScreenTrustMRI study
Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone in Locally Advanced Oesophageal Squamous Cell Carcinoma
Findings from the ESCORT-NEO/NCCES01 study
EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients
Extension to already existing indications in ALK-positive anaplastic large cell lymphoma and unresectable inflammatory myofibroblastic tumour concerns the treatment of children from 1 year of age
Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with EGFR-mutated NSCLC and Leptomeningeal Metastases
Findings from the BLOSSOM study
CAR22 Shows Durable Efficacy After a Single Infusion in Patients with Large B-Cell Lymphoma Who Relapse After CAR19 Therapy
Findings from the CARdinal-22 study
FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma
Evidence for efficacy is based on the results from the KEYNOTE-868/NRG-GY018 study
A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients with ROS1-positive NSCLC
Findings from the TRUST-I study
After 5 Years of Follow-Up, the Median PFS Has Yet To Be Reached in Patients with ALK-positive Advanced NSCLC Treated with First-Line Lorlatinib
Findings from the CROWN study